Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials.
To review the inhibitory effect of preventive approaches on recurrence after operation in patients with hepatocellular carcinoma (HCC), we summarized all available publications reporting randomized control trial indexed in PubMed. The treatment approaches presented above included pre-operative transcatheter arterial chemoembolization (TACE), post-operative TACE, systemic or locoregional chemotherapy, immunotherapy, Interferons and acyclic retinoic acid. Although no standard treatment has been established, several approaches presented promising results, which were both effective and tolerable in post-operative patients. Pre-operative TACE was not effective on prolonging survivals, while post-operative TACE was shown with both disease-free survival and overall survival benefits in some papers, however, it was also questioned by others. Systemic chemotherapy was generally not effective on prolonging survival but also poorly tolerated for its significant toxicities. Adoptive immunotherapy using LAK cells was proved to be beneficial to patients' survival in a recent paper. Interferon alpha and Interferon beta can inhibit recurrence in HCC patients with HCV infection background, though the mechanism is not fully understood. Acyclic retinoic acid was shown to decrease multi-centric recurrence after operation, which was reported by only one group. In conclusion, several adjuvant approaches have been studied for their efficacy on recurrence in HCC patients in randomized control trials; however, multi-centric randomized control trial is still needed for further evaluation on their efficacy and systemic or local toxicities; in addition, new adjuvant treatment should be investigated to provide more effective and tolerable methods for the patients with HCC after operation.
Sun
Hui-Chuan
HC
Associate Professor of Surgery, Liver Cancer Institute and Zhong Shan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. sunhc@zshospital.com
Tang
Zhao-You
ZY
D006528:Carcinoma, Hepatocellular / Q000517:prevention & control / Q000601:surgery* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000517:prevention & control / Q000601:surgery* / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D055502:Secondary Prevention